COMP <GO>
MED vs KO // ENTERPRISE SCALE & MARKET CAP
MEDIFAST INC (NYSE) VS. Coca-Cola Company (NYSE) • 15-METRIC TALLY: MED 1
— KO 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: KO
LAST: $12.26 (-0.16%) • MKT CAP: $137.1M
market-cap
$137.1M
LAST: $92.82 (+1.19%) • MKT CAP: $399.30B
market-cap
$399.30B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MED VS. KO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MED | KO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.30% | 61.60% | +9.70 | MED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 25.30% | -35.50 | KO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 26.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.91% | 1.33% | -0.42 | KO | /fcf-yield <GO> |
| Operating Margin | -3.70% | 28.70% | -32.40 | KO | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 27.30% | -32.20 | KO | /net-margins <GO> |
| Revenue Growth (YoY) | -36.00% | 1.90% | -37.90 | KO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.14% | 2.20% | -2.06 | KO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.71 | 6.84 | -2.13 | KO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | KO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 56.8 | -2.53 | KO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 28.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $137.1M | $399.30B | -$399.17B | KO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MED REV | KO REV | MED GROSS % | KO GROSS % | MED FCF | KO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $385.8M | $47.94B | 71.3% | 61.6% | $1.2M | $5.30B |
| FY 2024 | $602.5M | $47.06B | 73.8% | 61.1% | $17.0M | $4.74B |
| FY 2023 | $1.07B | $45.75B | — | — | $147.7M | $9.54B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MED // BETA —
KO // BETA 0.92